worldwide. Since the 16th century, influenza pandemics have been described at intervals ranging between 10 and 50 years with varying severity and impact. Influenza virus is a common human pathogen that has caused serious respiratory illness and death over the past century. It was first described in the 1918 pandemic and made resurgence in April 2009 in the form of a triple-reassortant influenza A virus, which is composed of a combination of human, swine, and Eurasian avian strains.
In March of 2009 a novel strain of swine origin influenza A (H1N1) virus (S-OIV) was detected in Mexico. It has now spread to the rest of the world. With over 170,000 laboratory-confirmed cases worldwide, the World Health Organization (WHO) has declared a global pandemic. 3, 4 
H1N1 influenza virus
Many animal influenza viruses naturally infect and circulate among a variety of avian and mammalian species. Most of these animal influenza viruses do not normally infect humans. However, on occasion, certain animal viruses do infect humans. Such infections have most often occurred as sporadic or isolated infections or sometimes resulted in small clusters of human infections. An influenza pandemic occurs when an animal influenza virus to which most humans have no immunity acquires the ability to cause sustained chains of human-to-human transmission leading to community-wide outbreaks. Such a virus has the potential to spread worldwide, causing a pandemic.The development of an influenza pandemic can be considered the result of the transformation of an animal influenza virus into a human influenza Swine flu virus, a respiratory virus initially known to cause infection in pigs, belongs to the Orthomyxoviridae family of viruses that include influenza A, influenza B, influenza C and thogotoviruses. Swine flu virus generally circulates throughout the year, but the disease mostly occurs during the late fall and early winter season. The most commonly circulating strains of swine flu virus isolated from pigs in the United States are H1N1, H1N2, H3N2 and H3N1, which belong to the influenza A subtype. In the past, the Centers for Disease Control and Prevention (CDC) have received reports of approximately one human swine influenza virus infection every one to two years in the United States but a sustained pattern of human to-human transmission has been seen to occur only recently. 2 The place of origin of the virus is unknown. This is a new influenza A (H1N1) virus that has never before circulated among humans. This virus is not related to previous or current human seasonal influenza viruses. H1N1pdm (also referred to as S-OIV) is a newly emergent human influenza A virus that is closely related to a number of currently circulating pig viruses in the 'classic North American' and 'Eurasian' swine influenza virus lineages. To reveal the early molecular epidemiology of the H1N1pdm, particularly its spatial patterning and evolutionary dynamics, an evolutionary analysis on available genome sequence data sampled globally was performed. 5 The pandemic (H1N1) 2009 influenza virus differs in its pathogenicity from seasonal influenza in two key aspects. First, as the majority of human population has little or no preexisting immunity to the virus, the impact of the infection has been in a wider age range, in particular among children and young adults. Secondly, the virus can infect the lower respiratory tract and cause rapidly progressive pneumonia especially in children and young to middle-aged adults. 6
Mode of transmission
The virus is transmitted from person-to-person as easily as the normal seasonal flu and can be passed to other people by inhalation of infectious droplets and droplet nuclei, by direct contact, and possibly, by indirect (fomite) contact, with self inoculation on to the upper respiratory tract or conjunctival mucosa [7] [8] [9] . There are no known instances of people getting infected by exposure to pigs or other animals. The incubation period appears to be approximately 2-3 days, but could range up to 7 day. 6
The global scenario A novel influenza A (H1N1) virus of swine origin emerged among people in Mexico during the spring of 2009 and spread with travelers worldwide, resulting in the first influenza pandemic since 1968. On April 23, several cases of severe respiratory illness laboratory Genetic reassortment: a process in which genes from animal and human influenza viruses mix together to create a human-animal influenza reassortant virus;
Genetic mutation: a process in which genes in an animal influenza virus change allowing the virus to infect humans and transmit easily among them.
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confirmed as swine-origin influenza A (H1N1) virus (S-OIV) infection were communicated to the PAHO. 10 On April 21, 2009, CDC reported that two recent cases of febrile respiratory illness in children in southern California had been caused by infection with genetically similar swine influenza A (H1N1) viruses. Neither child had known contact with pigs, resulting in concern that human-to-human transmission might have occurred. 11 Within two months, the virus quickly spread globally. 7 The most active areas of pandemic influenza virus transmission currently are in parts of Southeast Asia, West Africa, and in the tropical zone of the Americas. After a period of sustained pandemic influenza transmission in Thailand over the past two months, overall activity now appears to be decreasing. In West Africa, limited data suggests that active transmission of pandemic influenza virus persists without clear evidence of a peak in activity. In Central America and in the tropical zone of South America, an increasing trend of respiratory disease activity associated with circulation of pandemic influenza virus has been reported since early March 2010 in an increasing number of countries. Although pandemic influenza virus continues to be the predominant influenza virus circulating worldwide, seasonal influenza B viruses are predominate in East Asia, and have been increasingly detected at low levels across southeast and western Asia, eastern Africa, and in parts of Europe.
In Southeast Asia, pandemic influenza virus transmission has remained active and geographically widespread in Thailand since mid February 2010 and has been increasing since early March in Malaysia. In Thailand, the overall intensity of respiratory disease activity was reported to be low to moderate, and activity now appears to decreasing since mid March 2009; 10-22% of sentinel respiratory samples from patients with ILI tested positive for pandemic influenza during the most recent reporting week. In Malaysia, limited data suggests increasing detections of pandemic H1N1 cases over the past two weeks, although the extent and severity of illness is not period pandemic 
Sepsis syndrome
Other complications can include musculoskeletal system (rhabdomyolysis) and cardiac (myocarditis) dysfunction.
• Any other condition or clinical presentation requiring hospital admission for clinical management.
• Any of the 'danger signs' of disease progression listed below.
Signs and symptoms of progressive disease 'Danger signs'
Patients who present initially with uncomplicated influenza may progress to more severe disease. Progression can be rapid (i.e. within 24 hours). The following are some of the indicators of progression, which would necessitate an urgent review of patient management:
• Symptoms and signs suggesting oxygen impairment or cardiopulmonary insufficiency:
-Shortness of breath (with activity or at rest), difficulty in breathing, cyanosis haemoptysis, chest pain, and low blood pressure;
-In children, fast or laboured breathing/ chest indrawing/stridor; and -Hypoxia (<90% on air), as indicated by pulse oximetry.
• Symptoms and signs suggesting CNS complications:
- Antiviral drugs: There are two approved antiviral drugs for treatment of pandemic influenza. These are the neuraminidase inhibitors oseltamivir and zanamivir. 14, [16] [17] [18] There are different approaches for different category of patients for treatment. For patients with symptoms of severe illness, oseltamivir should be started immediately, no matter when the illness started and without waiting for laboratory results to confirm infection. For patients at higher risk for serious disease from pandemic influenza, treatment should be started with either oseltamivir or zanamivir as soon as possible after the onset of symptoms. People who are not from a higher risk group but who have persistent or rapidly worsening symptoms should be treated with antivirals. These symptoms include difficulty breathing or a high fever that lasts beyond three days.
In all cases, where oseltamivir is unavailable or cannot be used for any reason, zanamivir may be given. Antivirals should only be used when prescribed by a qualified health care provider, as they will be able to assess each situation and make the appropriate decisions on care.
For oseltamivir, the standard adult treatment course is one 75 mg capsule twice a day for five days. For severe or prolonged illness, physicians may decide to use a higher dose or continue the treatment for longer. Consideration may be given to the use of higher doses up to 150 mg bid, and longer duration of treatment depending on clinical response (up to 10 days). This recommendation applies to all patient groups, including pregnant women, and young children <5 years, including neonates.
Zanamivir is taken as a powder by inhalation. The recommended dose for treatment of adults and children from the age of 5 years is two inhalations (2 x 5mg) twice daily for five days.
Reduction of dose of oseltamivir is recommended for person with creatinine clearance below 30ml/min. Immunoglobulin or other unapproved therapies, steroids should not be given. The dose and dosage of oseltamivir should be completed preferably supervised. Oseltamivir is a well tolerated medicine. 
Prevention and Control
Resistance to oseltamivir has been increased worldwide. [19] [20] [21] [22] So, prevention and control of this infection is important. To minimize exposure to infection is the key to control. For this, individuals and communities should take measures like social distancing, respiratory etiquette, hand hygiene, and household ventilation. These are the most feasible measures available to reduce or delay disease. 23 At individual level it is adviced to cover nose and mouth with a tissue/cloths during cough or sneeze and throw the tissue in the trash after use, washing hands often with soap and water, especially after coughing or sneezing (if soap and water are not available, use an alcohol-based hand rub and avoid touching eyes, nose or mouth, stay home if get sick and contact health care providers if there is fever with breathing difficulty. 14, 24 People with exposure to an infected person and a higher risk of developing severe or complicated illness, should have to closely monitor for symptoms, followed by prompt early antiviral treatment if required 25, 26 . In case of mild illness, patients should be provided with supportive care at home by a designated caregiver and only referred to health care facilities if they deteriorate or develop danger signs. Separation of sick from well individuals, with rigorous respiratory etiquette and hygiene measures should be practiced. 23 People with influenza-like illness should remain at home until at least 24 hours after they are free of fever (temperature of 100° F [37.8°C] or more), or signs of a fever without the use of fever-reducing medications24. In health-care settings, a system of triage, patient separation, prioritization of use of antiviral medicines and personal protective equipment (PPE) according to risk of exposure, and patient management should be in Health workers are given first priority for early vaccination to protect themselves and their patients.
Other groups at higher risk for severe illness should also be considered as priorities. A single dose of vaccine is recommended in adults and adolescents from 10 years of age and above. Where national authorities have made children a priority for early vaccination, experts are advising one dose of vaccine to as many children as possible over the age of 6 months as and younger than 10 years of age.
Recommendations on numbers of dosages may need to be adapted rapidly as new data emerges. National authorities will develop and implement vaccination plans based on circumstances within the country. 27 CDC is encouraging anyone who wants to protect themselves against 2009 H1N1 to get vaccinated. The U.S. Food and Drug Administration (FDA) has approved the use of one dose of vaccine against 2009 H1N1 influenza virus for persons 10 years of age and older. For children who are 6 months through 9 years of age, two doses of the vaccine are recommended. These two doses should be separated by 4 weeks. Infants younger than 6 months of age are too young to get any influenza vaccine. 24 There is shortage of vaccine supply worldwide. There is need for more effective newer vaccines. Fu-Shi Quan and et el generated influenza virus-like particles (VLPs) containing proteins derived from the A/ California/04/2009 virus, and tested their efficacy as a vaccine in mice. A single intramuscular vaccination with VLPs provided complete protection against lethal challenge. This study demonstrates that VLP vaccination provides highly effective protection against the 2009 pandemic influenza virus. The results indicate that VLPs can be developed into an effective vaccine, which can be rapidly produced and avoid the need to isolate high growth reassortants for egg-based production. 28 Surveillance IEDCR is National Influenza Center (NIC), Bangladesh nominated by WHO. Influenza surveillance is being conducted since 2007 in 12 hospitals covering all the 6 administrative divisions of the country. A community site is also functioning in Kamalapur, Dhaka since 2004. Since September 2009 DMCH and NIDCH has been included in sentinel surveillance This surveillance system is helping us to understand the spread and type of influenza virus circulating in this country.
The National Rapid Response Team (NRRT) is under 7/24 alert and conducting investigation of reported cases of suspected Influenza A (H1N1).
The Civil Surgeons of all districts are directed by the Director General of Health Services to keep themselves prepared for tackling the situation. They are being updated regularly on Pandemic Influenza H1N1 2009. 12
Defining custer
A cluster of pandemic influenza 2009 is defined as two or more suspect, probable or confirmed cases of pandemic influenza 2009 found at a time in a localized area, having evidence of transmission among them.
Objective of defining cluster 1. Specimen from one or two persons will be tested 2. If found to be positive, other members of the cluster will be regarded as cases 3. Members of the cluster will be treated with Oseltamivir and other supportive treatment 4. Pharmaceutical and non pharmaceutical interventions will be under taken to limit the spread 5. Small cluster: <25 6. Large cluster: >25
